Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 1/2022

22.11.2021 | original report

Clinical characteristics and prognostic value of 1q21 gain detected by fluorescence in situ hybridization in patients with newly diagnosed multiple myeloma

verfasst von: Xiao Xiao, Xinchen Fang, Wen Yao, Zhu Huaiping

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

Objectives

This study aimed to investigate the clinical characteristics and prognostic impact of 1q21 gain in patients with newly diagnosed multiple myeloma (MM).

Methods

This was a retrospective study of 197 patients with newly diagnosed MM. Fluorescence in situ hybridization was performed to detect six cytogenetic abnormalities: gain(1q21), del(17p), del(13q14), t(4;14), t(14;16), and t(11;14).

Results

We showed that 57.8% of patients with MM had 1q21 gain. The patients with 1q21 gain had lower IgM (0.39 vs 1.14 g/L, P = 0.037) and higher platelet count (177.62109/l vs 148.29109/l, P = 0.018) than those without 1q21 gain, and were more likely to be accompanied by del(13q14) (P < 0.001) or t(4;14) (P = 0.017).

Conclusions

We showed that 1q21 gain was associated with del(13q14) and t(4;14) increase, but it had no effect on prognosis of patients with newly diagnosed MM.
Literatur
1.
Zurück zum Zitat Brigle K, Rogers B. Pathobiology and diagnosis of multiple myeloma. Semin Oncol Nurs. 2017;33(3):225–36. CrossRef Brigle K, Rogers B. Pathobiology and diagnosis of multiple myeloma. Semin Oncol Nurs. 2017;33(3):225–36. CrossRef
2.
Zurück zum Zitat Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, et al. Revised international staging system for multiple myeloma: a report from International MYELOMA working group. J Clin Oncol. 2015;33(26):2863–9. CrossRef Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, et al. Revised international staging system for multiple myeloma: a report from International MYELOMA working group. J Clin Oncol. 2015;33(26):2863–9. CrossRef
3.
Zurück zum Zitat Manier S, Salem KZ, Park J, et al. Genomic complexity of multiple myeloma and its clinical implications. Nat Rev Clin Oncol. 2017;14(2):100–13. CrossRef Manier S, Salem KZ, Park J, et al. Genomic complexity of multiple myeloma and its clinical implications. Nat Rev Clin Oncol. 2017;14(2):100–13. CrossRef
4.
Zurück zum Zitat Byun JM, Dong-Yeop S, Junshik H, et al. Distinct predictive impact of FISH abnormality in proteasome inhibitors and immunomodulatory agents response: redefining high-risk multiple myeloma in Asian patients. Cancer Med. 2018;7(3):831–41. CrossRef Byun JM, Dong-Yeop S, Junshik H, et al. Distinct predictive impact of FISH abnormality in proteasome inhibitors and immunomodulatory agents response: redefining high-risk multiple myeloma in Asian patients. Cancer Med. 2018;7(3):831–41. CrossRef
5.
Zurück zum Zitat Fonseca R, Van Wier SA, Chng WJ, et al. Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. Leukemia. 2006;20(11):2034–40. CrossRef Fonseca R, Van Wier SA, Chng WJ, et al. Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. Leukemia. 2006;20(11):2034–40. CrossRef
6.
Zurück zum Zitat Cremer FW, Bila J, Buck I, et al. Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics. Genes Chromosom Cancer. 2005;44(2):194–203. CrossRef Cremer FW, Bila J, Buck I, et al. Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics. Genes Chromosom Cancer. 2005;44(2):194–203. CrossRef
7.
Zurück zum Zitat Fonseca R, Blood EA, Oken MM, et al. Myeloma and the t(11;14)(q13;q32); evidence for a biologically defifined unique subset of patients. Blood. 2002;99:3735–41. CrossRef Fonseca R, Blood EA, Oken MM, et al. Myeloma and the t(11;14)(q13;q32); evidence for a biologically defifined unique subset of patients. Blood. 2002;99:3735–41. CrossRef
8.
Zurück zum Zitat Drach J, Ackermann J, Fritz E, et al. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood. 1998;92:802–9. CrossRef Drach J, Ackermann J, Fritz E, et al. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood. 1998;92:802–9. CrossRef
9.
Zurück zum Zitat Chiecchio L, Protheroe RKM, Ibrahim AH, et al. Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma. Leukemia. 2006;20:1610–7. CrossRef Chiecchio L, Protheroe RKM, Ibrahim AH, et al. Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma. Leukemia. 2006;20:1610–7. CrossRef
10.
Zurück zum Zitat Decaux O, Lodé L, Minvielle S, et al. Genetic abnormalities in multiple myeloma: role in oncogenesis and impact on survival. Rev Med Interne. 2007;28:677–81. CrossRef Decaux O, Lodé L, Minvielle S, et al. Genetic abnormalities in multiple myeloma: role in oncogenesis and impact on survival. Rev Med Interne. 2007;28:677–81. CrossRef
11.
Zurück zum Zitat Avet-Loiseau H, Attal M, Campion L, et al. Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival. J Clin Oncol. 2012;30(16):1949–52. CrossRef Avet-Loiseau H, Attal M, Campion L, et al. Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival. J Clin Oncol. 2012;30(16):1949–52. CrossRef
12.
Zurück zum Zitat Smol T, Dufour A, Tricot S, et al. Combination of t(4;14),del(17p13), del(1p32) and 1q21 gain FISH probes identifies clonal heterogeneity and enhances the detection of adverse cytogenetic profiles in 233 newly diagnosed multiple myeloma. Mol Cytogenet. 2017;10:26. CrossRef Smol T, Dufour A, Tricot S, et al. Combination of t(4;14),del(17p13), del(1p32) and 1q21 gain FISH probes identifies clonal heterogeneity and enhances the detection of adverse cytogenetic profiles in 233 newly diagnosed multiple myeloma. Mol Cytogenet. 2017;10:26. CrossRef
13.
Zurück zum Zitat Chng WJ, Dispenzieri A, Chim C‑S, et al. IMWG consensus on risk stratification in multiple myeloma. Leukemia. 2014;28(2):269–77. CrossRef Chng WJ, Dispenzieri A, Chim C‑S, et al. IMWG consensus on risk stratification in multiple myeloma. Leukemia. 2014;28(2):269–77. CrossRef
15.
Zurück zum Zitat Nemec P, Zemanova Z, Greslikova H, et al. Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapy. Biol Blood Marrow Transplant. 2010;16(4):548–54. CrossRef Nemec P, Zemanova Z, Greslikova H, et al. Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapy. Biol Blood Marrow Transplant. 2010;16(4):548–54. CrossRef
16.
Zurück zum Zitat Avet-Loiseau H, Attal M, Moreau P, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood. 2007;109(8):3489–95. CrossRef Avet-Loiseau H, Attal M, Moreau P, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood. 2007;109(8):3489–95. CrossRef
17.
Zurück zum Zitat Bang SM, Kim YR, Cho HI, et al. Identification of 13q deletion, trisomy 1q, and IgH rearrangement as the most frequent chromosomal changes found in Korean patients with multiple myeloma. Cancer Genet Cytogenet. 2006;168(2):124–32. CrossRef Bang SM, Kim YR, Cho HI, et al. Identification of 13q deletion, trisomy 1q, and IgH rearrangement as the most frequent chromosomal changes found in Korean patients with multiple myeloma. Cancer Genet Cytogenet. 2006;168(2):124–32. CrossRef
Metadaten
Titel
Clinical characteristics and prognostic value of 1q21 gain detected by fluorescence in situ hybridization in patients with newly diagnosed multiple myeloma
verfasst von
Xiao Xiao
Xinchen Fang
Wen Yao
Zhu Huaiping
Publikationsdatum
22.11.2021
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 1/2022
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-021-00774-6